Matches in UGent Biblio for { <https://biblio.ugent.be/publication/1165613#aggregation> ?p ?o. }
Showing items 1 to 48 of
48
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B286305.
- aggregation creator B286306.
- aggregation creator B286307.
- aggregation creator B286308.
- aggregation creator B286309.
- aggregation creator B286310.
- aggregation creator B286311.
- aggregation creator B286312.
- aggregation creator B286313.
- aggregation creator B286314.
- aggregation creator B286315.
- aggregation creator B286316.
- aggregation creator B286317.
- aggregation creator B286318.
- aggregation creator B286319.
- aggregation creator B286320.
- aggregation creator person.
- aggregation date "2010".
- aggregation format "application/pdf".
- aggregation hasFormat 1165613.bibtex.
- aggregation hasFormat 1165613.csv.
- aggregation hasFormat 1165613.dc.
- aggregation hasFormat 1165613.didl.
- aggregation hasFormat 1165613.doc.
- aggregation hasFormat 1165613.json.
- aggregation hasFormat 1165613.mets.
- aggregation hasFormat 1165613.mods.
- aggregation hasFormat 1165613.rdf.
- aggregation hasFormat 1165613.ris.
- aggregation hasFormat 1165613.txt.
- aggregation hasFormat 1165613.xls.
- aggregation hasFormat 1165613.yaml.
- aggregation isPartOf urn:issn:0091-2700.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults".
- aggregation abstract "Telcagepant is a novel, orally active, and selective calcitonin gene-related peptide receptor antagonist being developed for acute treatment of migraine with and without aura. Three separate clinical studies were conducted to evaluate the pharmacokinetics and tolerability of telcagepant following single oral doses in healthy young and elderly men and women and multiple oral doses in men. Telcagepant was rapidly absorbed with a time to maximum concentration of approximately 1.5 hours. The terminal half-life was approximately 6 hours. A greater than dose-proportional increase was observed in the area under the plasma concentration versus time curve from zero to infinity. Following twice-daily dosing, with each dose separated by 2 hours, steady state was achieved in approximately 3 to 4 days with an accumulation ratio of approximately 2. There were no clinically meaningful pharmacokinetic differences when compared across age and gender. Telcagepant was generally well tolerated up to single doses of 1200 mg and multiple doses of 400 mg twice daily.".
- aggregation authorList BK568572.
- aggregation endPage "1376".
- aggregation issue "12".
- aggregation startPage "1367".
- aggregation volume "50".
- aggregation aggregates 1181288.
- aggregation isDescribedBy 1165613.
- aggregation similarTo 0091270010361741.
- aggregation similarTo LU-1165613.